NOT ALL EQUAL –
Feb. 17, 2022 – These gaps in care put patients struggling with OUD at risk, and many need effective treatment now more than ever. Understanding these disparities can help state policymakers improve their states’ OTP treatment systems and expand access to medications for OUD. Pew’s analysis found that:
Many opioid treatment programs offer a limited selection of FDA-approved medications for OUD.
While nearly all OTPs provide methadone—the most highly regulated form of medication for OUD—based on the Substance Abuse and Mental Health Services Administration (SAMHSA) data, 60.5% did not offer injectable naltrexone and nearly 20% of OTPs nationally did not offer buprenorphine in 2020.
